VectorY Therapeutics and Annogen have announced a new agreement to work toward developing vectorized antibody therapies for Parkinson’s disease and other neurological conditions. “We are delighted to work together with Annogen on novel tailored cell-specific promoters to enhance VectorY’s transformative AAV-vectorized antibody platform and its potential to…
Medicines for Parkinson’s disease in patients with persistent intolerable abdominal pain showed short and limited usefulness in treating this debilitating non-motor symptom, a study in Japan reported. Nonetheless, researchers found that Duodopa/Duopa,…
A Phase 2b clinical trial testing the investigational oral therapy mesdopetam, which aims to reduce levodopa-induced dyskinesia (involuntary movements) in people with Parkinson’s disease, did not reach its main goal. However, some promising reductions in dyskinesia measures were seen with the treatment. Top-line results from the trial were…
A 12-week electroacupuncture (EA) regimen in Parkinson’s disease patients along with standard medications was well tolerated and led to improved motor function and some relief from constipation, a recent study showed. Patients also reported gains in quality of life compared with those only receiving standard of care medications. “Our…
A new metric called the Parkinson’s Disease Social Functioning Scale (PDSFS) can measure social functioning in people with Parkinson’s disease, a new study reports. PDSFS scores show associations with the severity of psychiatric symptoms, suggesting better treatment of symptoms could improve patients’ ability to function in social settings, researchers…
Seal Rock Therapeutics says its novel oral therapy program SRT-055, which aims to treat Parkinson’s disease and other neurological disorders, showed powerful neuroprotective effects in preclinical experiments. The company now plans to advance the program’s development for Parkinson’s — and then will move toward the treatment of…
IRLAB Therapeutics has selected a dopamine receptor agonist candidate called IRL1117 to advance as a Parkinson’s disease treatment, potentially as a longer-lasting alternative to levodopa with lesser side effects. IRL1117 is designed to be a once-daily oral therapy for the hallmark symptoms of Parkinson’s — tremors, rigidity, and slowness of…
Subthalamic deep brain stimulation (DBS) significantly eases motor and non-motor symptoms in people with early-onset Parkinson’s disease, a new study suggests. In fact, data showed that individuals with this early-onset form of the neurodegenerative disorder saw more than a 50% improvement, or lessening of motor symptoms, on one…
Levels of nerve cell pentraxin proteins found in the cerebrospinal fluid (CSF) surrounding the brain and spinal cord are associated with motor and cognitive decline in people with Parkinson’s disease and related conditions, a study suggests. As such, these nerve pentraxins may serve as predictive biomarkers for both…
Increasing doses of KM-819, a potential therapy being developed by Fascinate Therapeutics for Parkinson’s disease, showed a favorable safety profile in healthy older adults, according to data from the now-completed Part 1a of a Phase 2 trial. The placebo-controlled trial (NCT05670782), which was launched last year, is…
Get regular updates to your inbox.